Gene Therapy Stock Moves Higher on Analyst Upgrade

Sangamo Therapeutics stock is eyeing its sixth straight win today

Deputy Editor
Jul 7, 2020 at 10:13 AM
facebook twitter linkedin


The shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) are up 1.7% at $10 at last check, after moving higher on the charts in their last five-consecutive closes. Additionally, SunTrust Robinson just initiated coverage on the gene therapy specialist with a "buy" rating and a price target of $22 -- a 120% premium to current levels.

Coming into today, the majority of analysts covering SGMO shared this bullish sentiment. Of the six in coverage, four brokerages rated it a "strong buy," while just two called it a "hold." Meanwhile, the consensus 12-month target price of $20.17 is more than double the equity's current perch and sits at a level the stock hasn't touched since April 2018.

The options pits have taken a bullish approach to SGMO, too. On the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) the security sports a 50-day call/put volume ratio of 22.21, which sits in the highest percentile of its annual range, indicating an unusually heavy appetite for calls of late. 

Echoing this, Sangamo stock's Schaeffer's put/call open interest ratio (SOIR) of 0.10 sits in just the 2nd percentile of its annual range, suggesting short-term option players have rarely been more call-biased during the past 12 months.

SGMO saw a notable rally off its mid-March, three-year low of $4.81, surging toward an annual high of annual high of $12 on June 1. The shares eventually gapped lower after weeks of consolidation just below the area and now both the $10 mark and the security's 20-day moving average are keeping the security from closing this bear gap, though it still boasts an 18% lead for the year. 

 

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!